For many individuals who have successfully navigated the arduous journey of breast cancer treatment, the conclusion of medical care—the final infusion, the last radiation session, or the end of a long course of medication—is meant to be a moment of celebration. However, for a significant portion of survivors, the physical and mental toll of the disease and its treatments does not simply dissipate when the formal protocol ends. Instead, a persistent cloud of cognitive disruption, often characterized by memory lapses, difficulty concentrating, and overwhelming exhaustion, can linger for years, profoundly impacting their quality of life.
Now, a team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has unveiled promising early evidence that a naturally occurring molecule, oxaloacetate, may offer a viable pathway to alleviating these debilitating symptoms. This discovery, detailed in a study published in JCO Oncology Advances, suggests that this molecule, which is fundamental to how human cells generate energy, could be a key to unlocking relief for patients who have long felt that their cognitive health was left behind in the wake of their cancer journey.
Understanding the Persistence of "Chemo Brain"
Cognitive impairment following a cancer diagnosis is a widespread and deeply frustrating concern. While the phenomenon is colloquially known as "chemo brain" or "brain fog," medical experts clarify that the etiology is rarely tied to a single source. Researchers estimate that between 15% and 25% of breast cancer survivors suffer from ongoing cognitive challenges, such as difficulties with memory, focus, and executive function, long after their initial diagnosis.
The persistence of these symptoms highlights a critical gap in survivorship care. Despite the prevalence of these issues, there are currently very few evidence-based treatments available to help patients regain their mental clarity. Dr. Patricia Ganz, the study’s first author and a distinguished professor of medicine at the David Geffen School of Medicine at UCLA and the UCLA Fielding School of Public Health, emphasizes the gravity of the situation. "Cancer-related cognitive impairment can persist long after treatment ends and can have a significant impact on a person’s daily life, yet we still have very few effective treatments for it," she notes.
The complexity of the condition stems from the fact that it is likely driven by a confluence of biological and environmental factors. Chemotherapy, while a frequent culprit, is only part of the equation. Endocrine therapies, chronic systemic inflammation, hormonal shifts induced by treatment, and the lingering psychological stress of a cancer diagnosis all contribute to the degradation of cognitive function. Because these processes overlap and interact in complex ways, finding a single intervention that addresses the underlying mechanisms of brain fog has proven to be a significant challenge for the oncology community.
Investigating the Role of Cellular Energy and Inflammation
To address this challenge, the UCLA team turned their attention to the intersection of inflammation and cellular metabolism. Scientists are increasingly interested in how the inflammatory response—which is frequently triggered by cancer and its various treatments—interferes with normal neural communication. One area of particular concern is glutamate signaling, a process essential for the efficient transmission of information between nerve cells. When this signaling is disrupted by inflammation, or when brain cells struggle to produce energy efficiently, the result is the classic "fog" reported by patients: a sense of mental sluggishness, an inability to multitask, and persistent, unexplained exhaustion.
Oxaloacetate caught the researchers’ interest because of its dual role in the body. Not only is it a vital component in the Krebs cycle—the process through which cells generate energy—but it also plays a regulatory role in glutamate metabolism. The researchers hypothesized that by supplementing with oxaloacetate, they might be able to stabilize these processes, essentially providing the brain with the fuel and the regulatory balance needed to overcome the metabolic interference caused by cancer treatments.
The Phase II Clinical Trial
To put this theory to the test, the UCLA researchers conducted a phase II clinical trial involving 18 women who had been diagnosed with early-stage breast cancer one to five years prior to the study. All participants reported experiencing substantial cognitive difficulties at the time of enrollment. The cohort was reflective of the typical patient population, with an average age of 50. Most of the participants had undergone chemotherapy, and nearly 90% were continuing to receive endocrine therapy, which is known to be associated with cognitive side effects.
The study design was straightforward but rigorous. Participants were instructed to take a 500-milligram supplement of oxaloacetate twice daily for a period of eight weeks. Throughout this window, the research team employed a variety of tools to track changes, including participant-reported questionnaires and standardized cognitive assessments. These tests were specifically designed to measure key executive functions, such as the ability to process information quickly, maintain attention, organize complex tasks, and manage planning. Furthermore, the researchers closely monitored for any potential side effects, as well as broader indicators of quality of life, including fatigue levels, sleep quality, anxiety, and depression.
Significant Improvements in Cognitive Function
The outcomes of the eight-week trial were remarkably encouraging. Of the 18 women who began the study, 16 completed the full duration of the treatment. Among those who finished, every single participant reported a noticeable improvement in their cognitive symptoms.
The data provided by the study’s primary measure of perceived cognitive impairment were particularly striking. Before the intervention, participants reported an average score of 29.1, a figure indicative of significant impairment. By the end of the eight-week study, that average had risen to 55.5—a score that shifted the participants out of the impaired range and into the category considered normal. Even more promising was the timeline of these improvements; participants began noting positive changes as early as four weeks into the trial, with those benefits tending to grow more pronounced as the supplementation continued.
Beyond subjective feelings of improved memory and concentration, the study provided objective evidence of change. Standardized cognitive testing confirmed improvements in both processing speed and executive function. Participants also reported substantial reductions in fatigue, particularly the kind of mental exhaustion that makes daily chores or professional obligations feel overwhelming. Many also noted improvements in their physical functional capacity, suggesting that the supplement’s impact extended to their general sense of vitality.
Safety and Future Directions
While the results are compelling, the research team remains cautious. As a phase II study with a small sample size and no placebo control, these findings are considered preliminary. It is impossible to definitively conclude that the oxaloacetate itself was the sole cause of the improvements, or to rule out a placebo effect.
Regarding safety, the supplement was generally well-tolerated. The most common side effects reported were gastrointestinal in nature, including nausea, indigestion, bloating, constipation, and diarrhea. Two participants chose to discontinue the trial due to these digestive issues, but no serious adverse events were recorded during the study period.
"These early findings give us a strong reason to continue studying oxaloacetate as a potential approach for managing cognitive problems after breast cancer treatment," Dr. Ganz stated.
To that end, the UCLA team is already taking steps to build upon these results. They are currently preparing a larger, randomized, placebo-controlled phase II clinical trial, which is expected to begin enrolling breast cancer survivors with cognitive impairment in late 2026. This next phase will be critical in determining whether the benefits observed in the initial trial can be replicated under more stringent conditions.
Simultaneously, the researchers are conducting preclinical studies in mice to gain a deeper understanding of the biological mechanisms at play. By exploring how oxaloacetate influences the brain and body in animal models, the team hopes to confirm whether the molecule can indeed mitigate the systemic factors—such as fatigue and impaired physical function—that characterize the post-cancer experience. The research, which has received partial financial backing from the National Cancer Institute and the Breast Cancer Research Foundation, marks an important step toward providing survivors with the tools they need to reclaim their cognitive health and long-term quality of life. The study authors, including Dr. Ganz, Dr. Kathleen Van Dyk, Dr. Catherine M. Crespi, Laura Petersen, Dr. Mina Sedrak, and Dr. Julienne Bower, continue to lead this effort, keeping their focus firmly on translating these laboratory and clinical insights into practical solutions for patients.
